MX2021004149A - Biblioteca de anticuerpos y método. - Google Patents

Biblioteca de anticuerpos y método.

Info

Publication number
MX2021004149A
MX2021004149A MX2021004149A MX2021004149A MX2021004149A MX 2021004149 A MX2021004149 A MX 2021004149A MX 2021004149 A MX2021004149 A MX 2021004149A MX 2021004149 A MX2021004149 A MX 2021004149A MX 2021004149 A MX2021004149 A MX 2021004149A
Authority
MX
Mexico
Prior art keywords
variants
antibody
methods
libraries
sup
Prior art date
Application number
MX2021004149A
Other languages
English (en)
Spanish (es)
Inventor
Richard Buick
Christopher Scott
Leona Mcgirr
Hugh Morgan
Natasha Campbell
James Mcclory
Anthony O'kane
Darragh Maccann
Original Assignee
Fusion Antibodies Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1817188.4A external-priority patent/GB201817188D0/en
Priority claimed from GBGB1904754.7A external-priority patent/GB201904754D0/en
Priority claimed from GBGB1905032.7A external-priority patent/GB201905032D0/en
Application filed by Fusion Antibodies Plc filed Critical Fusion Antibodies Plc
Publication of MX2021004149A publication Critical patent/MX2021004149A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2021004149A 2018-10-22 2019-10-22 Biblioteca de anticuerpos y método. MX2021004149A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1817188.4A GB201817188D0 (en) 2018-10-22 2018-10-22 Antibody library
GBGB1904754.7A GB201904754D0 (en) 2019-04-04 2019-04-04 Antibody library and method
GBGB1905032.7A GB201905032D0 (en) 2019-04-09 2019-04-09 Antibody library and method
PCT/GB2019/053010 WO2020084298A1 (en) 2018-10-22 2019-10-22 Antibody library and method

Publications (1)

Publication Number Publication Date
MX2021004149A true MX2021004149A (es) 2021-06-15

Family

ID=68393020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004149A MX2021004149A (es) 2018-10-22 2019-10-22 Biblioteca de anticuerpos y método.

Country Status (10)

Country Link
US (2) US12378696B2 (cg-RX-API-DMAC7.html)
EP (1) EP3870607A1 (cg-RX-API-DMAC7.html)
JP (2) JP7853096B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210084509A (cg-RX-API-DMAC7.html)
CN (1) CN113195537A (cg-RX-API-DMAC7.html)
AU (1) AU2019365135B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007529A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115150A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004149A (cg-RX-API-DMAC7.html)
WO (1) WO2020084298A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7473339B2 (ja) * 2017-03-07 2024-04-23 エフ. ホフマン-ラ ロシュ アーゲー 代替の抗原特異的抗体変異体を発見するための方法
CN112289369B (zh) * 2020-12-15 2021-04-02 武汉华美生物工程有限公司 一种基于深度学习的抗体库构建方法及装置
CN114775065B (zh) * 2022-04-22 2026-01-06 武汉华美生物工程有限公司 一种半合成纳米抗体库构建方法和纳米抗体库
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途
CN121737857A (zh) * 2024-09-26 2026-03-27 上海循曜生物科技有限公司 增强FIX和FIXa活性的纳米抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011950A (es) * 1999-05-27 2002-05-06 Gov Health & Human Serv Inmunoconjugados que tienen alta afinidad de enlace.
WO2016188911A1 (en) * 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
CN109576292B (zh) * 2018-12-21 2022-11-29 深圳市爱思迪生物科技有限公司 一种抗体文库的构建方法及其应用

Also Published As

Publication number Publication date
WO2020084298A1 (en) 2020-04-30
US12378696B2 (en) 2025-08-05
JP2022512650A (ja) 2022-02-07
CN113195537A (zh) 2021-07-30
US20210388063A1 (en) 2021-12-16
KR20210084509A (ko) 2021-07-07
BR112021007529A2 (pt) 2021-08-03
JP7853096B2 (ja) 2026-04-28
AU2019365135A1 (en) 2021-05-13
JP2026016427A (ja) 2026-02-03
US20250382726A1 (en) 2025-12-18
AU2019365135B2 (en) 2026-08-13
EP3870607A1 (en) 2021-09-01
CA3115150A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
BR112021017801A2 (pt) Anticorpos biespecíficos anti-vbeta17/anti-cd123
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
WO2023076420A3 (en) Multispecific sars-cov-2 antibodies and methods of use
WO2019224711A3 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
WO2018170351A8 (en) Anti-phf-tau antibodies and uses thereof
EP4407622A3 (en) Neoantigen analysis
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
DE69826465D1 (de) Verfahren zur in vitro evolution von proteinfunktionen
PH12021553042A1 (en) Sorting with counter selection using sequence similar peptides
EP3812398A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
DE602005020743D1 (de) Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
AU2021313128A8 (en) Methods for middle down antibody characterization
WO2011146514A3 (en) Rapid isolation of monoclonal antibodies from animals
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
CY1109597T1 (el) Διαδικασια για την επιλογη υψηλης ομοιομορφιας σε ενα στοχο συνδετικων νουκλεϊνικων οξεων με δισδιαστατο διαχωρισμο
WO2020218951A3 (ru) Моноклональное антитело, которое специфически связывается с gitr
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
EP4438628A3 (en) Novel polypeptides
EP4253549A3 (en) Improved high-throughput combinatorial genetic modification system and optimized cas9 enzyme variants
MX2024011805A (es) Nuevos anticuerpos anti-fgfr2
MX2022011801A (es) Anticuerpos monoclonales contra acidos nucleicos modificados quimicamente y usos de los mismos.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
MX2023011710A (es) Anticuerpos miembro a de la familia 12 del dominio de lectina de tipo c (anti-clec12a) y usos de los mismos.
DE602006021324D1 (de) Verfahren zur herstellung stabiler b-lymphozyten